Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Expensify Q2 Sales $43.20M Miss $43.66M Estimate

Expensify Q2 Sales $43.20M Miss $43.66M Estimate

Expensify (NASDAQ:EXFY) reported quarterly sales of $43.20 million which missed the analyst consensus estimate of $43.66 million by 1.05 percent.

byBenzinga Newsdesk

August 11, 2022

1 minute read

Expensify (NASDAQ:EXFY) reported quarterly sales of $43.20 million which missed the analyst consensus estimate of $43.66 million by 1.05 percent.

Earnings

Looking Into Novavax’s Return On Capital Employed

By Benzinga Insights

May 24, 10:46 AM

Benzinga Pro data, Novavax (NASDAQ:NVAX) reported Q1 sales of $80.95 million. Earnings fell to a loss of $293.90…

NVAX

Biden’s Inflation Reduction Act Seen Cutting Up To $1.9 Trillion In Climate-Related Economic Damage, Latest Analysis Finds

By AJ Fabino

August 23, 1:16 PM

The White House Office of Management and Budget (OMB) on Tuesday released its first published analysis of avoided climate-related social costs resulting from a piece of legislation.

FCEL

FDA
News

FDA Advisers Back Pfizer’s Paxlovid, Vote Benefits Outweigh Risks For Treating Mild-to-moderate COVID-19 In Those At Risk Of Severe Disease

By Benzinga Newsdesk

March 16, 2:24 PM

-Reuters

PFE

What’s Going On With Virgin Galactic Stock Monday?

By Adam Eckert

June 10, 8:57 AM

Virgin Galactic has announced the successful completion of its "Galactic 07" flight carrying one researcher and three private astronauts. The researcher collected physiological data related to human spaceflight and examined the ability to administer accurate insulin doses in microgravity.

SPCE

Expensify Q2 Sales $43.20M Miss $43.66M Estimate

Related Posts

Looking Into Novavax’s Return On Capital Employed

Biden’s Inflation Reduction Act Seen Cutting Up To $1.9 Trillion In Climate-Related Economic Damage, Latest Analysis Finds

FDA Advisers Back Pfizer’s Paxlovid, Vote Benefits Outweigh Risks For Treating Mild-to-moderate COVID-19 In Those At Risk Of Severe Disease

What’s Going On With Virgin Galactic Stock Monday?